JAMA Network Home
Sign In
Editor's Pick Perspective

From Biological Insight to a New Class of Medicines for Hemophilia A

JAMA 10.1001/jama.2026.15612

September 09, 2026 at 8:00 AM EDT

Read the full article

In this Perspective, the 2026 Lasker-DeBakey Clinical Medical Research Award winners describe the development of a bispecific antibody that mimics blood coagulation factor VIII, revolutionizing the treatment of hemophilia, a life-threatening bleeding disorder caused by lack of factor VIII.

Corresponding Author: Takehisa Kitazawa, PhD, DVM, Research Division, Chugai Pharmaceutical Co Ltd, 216 Totsuka-cho, Totsuka-ku, Yokohama, Kanagawa 2448602, Japan (kitazawatkh@chugai-pharm.co.jp).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.15612?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090926

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks